Citadel Advisors’s Nemaura Medical, Inc. Common Stock NMRD Stock Holding History

Citadel Advisors’s Portfolio NMRD Stock Details NMRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,000	Closed	-$46K	–	14886
2021 Q4	$46K	Sell	10,000 -23,700	-70%	-$128K	﹤0.01%	13298
2021 Q3	$203K	Sell	33,700 -80,000	-70%	-$576K	﹤0.01%	11962
2021 Q2	$1.18M	Buy	113,700 +56,400	+98%	+$538K	﹤0.01%	7927
2021 Q1	$438K	Buy	+57,300	New	+$379K	﹤0.01%	9984

Other funds holding NMRD

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Citadel Advisors's NMRD Position: Q1 2024 in Review

Citadel Advisors sold out of Nemaura Medical, Inc. Common Stock (NMRD) in Q1 2024, closing a stake of 41,693 shares — an estimated $9.38K sold.

Citadel Advisors first reported a position in NMRD in Q2 2018 and held it in 6 quarters. The position peaked at $85K in Q3 2020. 2 funds tracked by Wall St. Rank hold NMRD as of Q1 2024.

Citadel Advisors reported no remaining Nemaura Medical, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 41,693 Nemaura Medical, Inc. Common Stock shares in Q1 2024, an estimated $9.38K.
Citadel Advisors first reported a position in Nemaura Medical, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
Citadel Advisors's Nemaura Medical, Inc. Common Stock position peaked at $85K in Q3 2020.
2 funds tracked by Wall St. Rank held Nemaura Medical, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.